Yuhan(000100) will expand cooperation with external research institutions to discover new drug candidates and strengthen research and development capabilities.
Yuhan said on the 1st that it signed a memorandum of understanding (MOU) with KMEDI hub to strengthen its innovative new drug pipeline.
Under the agreement, the two sides agreed to identify and carry out joint research projects for new drugs. They will also cooperate on mutual technical support, including strengthening research and development capabilities through researcher exchanges and sharing research facilities and advanced equipment. They will push to build a network related to the medical industry.
Yuhan plans to strengthen open innovation by leveraging KMEDI hub's specialized research personnel and new drug development research infrastructure. However, at this stage of the agreement, no specific joint research projects or candidate substances have been set. The two sides plan to flesh out collaboration needs and expand into joint research and technology cooperation.
Kim Yeol-hong, Yuhan's head of research and development (R&D), said, "For innovative new drug development, collaboration that organically links diverse research capabilities and infrastructure is important," and added, "By combining our respective strengths with KMEDI hub, we hope to identify promising new drug development projects and translate them into research and development outcomes."
Park Gu-seon, chair of KMEDI hub, said, "We will actively utilize specialized personnel and research infrastructure to support joint research and help strengthen the competitiveness of the domestic new drug development industry."